Delving into the Latest Updates on LXR Biotechnology, Inc. with Synapse

Overview

Basic Info

Introduction

LXR Biotechnology is a privately-owned corporation based in Richmond, California, which specializes in creating medical treatments for various illnesses through advanced research and development. The company was established by Scott Minick.

The mol. determinants of lysophosphatidic acid (LPA) in the activation of the G protein-coupled LPA receptor, EDG2, in yeast, were established as a preliminary study to the anal. of the EDG2 receptor in mammalian cells.Using induction of the FUS1:lacZ reporter system by LPAs of different structures, a structure-activity profile was developed for LPA in the activation of EDG2 and was compared with the activation of EDG4 and MAP kinases (ERK1 and ERK2).EDG2 activation was most dependent on two parameters.First, only LPA mols. with side chains of 16 or 18 carbons, but not 14 or 24 carbons, would activate lacZ.Second, only acyl-linked (ester) LPA analogs would activate, unlike the alkenyl-linked (ether) forms that were completely inactive.Substitutions at the sn-2 position were less criticalIn contrast to EDG2, EDG4 had a different structure-activity profile than EDG2 in yeast.EDG4-mediated activation of lacZ by LPA was strongly dependent on the sn-2 substitution.The acyl-linked analogs that activated EDG2 had no activity toward EDG4.Interestingly, the structure-activity profile for ERK1 and ERK2 matched very closely the profile for EDG4 but not EDG2.From these data, it is possible to suggest that EDG2 does not mediate MAP kinase activation in mammalian cells and, therefore, does not elicit the mitogenic response associated with LPA in serum.The similarities between the requirements for MAP kinase activation in fibroblasts and EDG4 activation in yeast suggests that EDG4 may be a mitogenic LPA receptor.

01 Jul 1999·Nutrition and CancerQ4 · MEDICINE

Antiapoptotic Activity of the Bowman-Birk Inhibitor Can Be Attributed to Copurified Phospholipids

Q4 · MEDICINE

Article

Author: Foehr, Matthew W. ; Goddard, J. Graham ; Bathurst, Ian C. ; Pemberton, Philip A. ; Tomei, L. David

Previous studies have shown that extracts from soy possess potent antiapoptotic activity in in vitro and in vivo models. We recently reported that this antiapoptotic activity can be attributed to the presence of specific phospholipids. In this study, a conventional preparation of the soy-derived Bowman-Birk inhibitor (BBI) was tested for antiapoptotic activity in a C3H/10T1/2 cell serum deprivation assay. The BBI preparation was separated into lipid- or protein-containing fractions by organic extraction. The lipid fraction contained only antiapoptotic activity; the protein fraction contained only enzyme inhibition activity. We therefore conclude that the antiapoptotic activity of the BBI preparation is due to specific phospholipids that copurify with BBI. These phospholipids retain their antiapoptotic activity after autoclave treatment, whereas autoclave treatment of the protein fraction results in a loss of its enzyme inhibition activity.

01 Aug 1998·Neurologic ClinicsQ3 · MEDICINE

AGING AND APOPTOSIS CONTROL

Q3 · MEDICINE

Review

Author: Tomei, L D ; Umansky, S R

The phenomenon of aging is distinct from processes associated with advanced age known to increase risk of diseases, such as cancer. Furthermore, the process of aging is not necessarily related to phenomena such as in vitro replicative senescence; however, any unifying hypothesis of aging must account for all age-dependent phenomena, including senescence. It is proposed that apoptosis forms the ultimate protective process for preservation of phenotypic fidelity in multicellular organisms since it is the process by which the organism detects damage and replaces the defective cell. Time-dependent degeneration of apoptosis control is the rate-limiting step in the process of aging.

100 Deals associated with LXR Biotechnology, Inc.

Login to view more data

100 Translational Medicine associated with LXR Biotechnology, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data